Drug Trial Radar · NCT02797587
Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)
Last checked: Nov 20, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Jul 19, 2017
Primary completion
Apr 30, 2020
Study completion Dec 15, 2020
Sponsor
- Lead sponsor
- Boston Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- First posted
- Jun 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized controlled trial (RCT) to compare the effects of varenicline, cytisine, and nicotine replacement therapy (NRT) to reduce: 1) alcohol use and craving, 2) smoking; and 3) inflammation and risk for coronary heart disease (CHD) and mortality among 400 HIV-infected Russians, with heavy alcohol consumption and tobacco use.
Conditions
- HIV Infection
- Alcohol Use
- Smoking
Interventions
VareniclineDrug
1 week starter kit followed by 1mg twice daily for 12 weeks.
CytisineDrug
Multi-daily dosing, range 3-9 mg daily for 25 days.
Nicotine Replacement TherapyDrug
Mouth spray dosing based on standard recommendations tapered over 8 weeks.
Varenicline PlaceboDrug
1 week starter kit followed by 1 pill twice daily for 12 weeks.
Cytisine PlaceboDrug
Multi-daily dosing for 25 days.
Nicotine Replacement Therapy PlaceboDrug
Mouth spray dosing based on standard recommendations tapered over 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent heavy drinking days in past 30 daysTime frame: Participants will be followed for up to 12 months (primary endpoint at 3 month)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First St. Petersburg Pavlov State Medical University
Saint Petersburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.